Published in Shock on March 01, 2004
Perfusion vs. oxygen delivery in transfusion with "fresh" and "old" red blood cells: the experimental evidence. Transfus Apher Sci (2010) 1.07
Survival time in severe hemorrhagic shock after perioperative hemodilution is longer with PEG-conjugated human serum albumin than with HES 130/0.4: a microvascular perspective. Crit Care (2008) 0.97
Blood substitutes: evolution from noncarrying to oxygen- and gas-carrying fluids. ASAIO J (2013) 0.91
Therapeutic options to minimize allogeneic blood transfusions and their adverse effects in cardiac surgery: a systematic review. Rev Bras Cir Cardiovasc (2015) 0.86
Microvascular experimental evidence on the relative significance of restoring oxygen carrying capacity vs. blood viscosity in shock resuscitation. Biochim Biophys Acta (2008) 0.84
Examining and mitigating acellular hemoglobin vasoactivity. Antioxid Redox Signal (2012) 0.83
Effects of plasma viscosity modulation on cardiac function during moderate hemodilution. Asian J Transfus Sci (2010) 0.82
Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. Nat Med (2005) 3.19
Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug Discov Today (2003) 2.72
Oxygen gradients in the microcirculation. Physiol Rev (2003) 2.53
Low nitric oxide bioavailability contributes to the genesis of experimental cerebral malaria. Nat Med (2006) 2.33
Resuscitation with polyethylene glycol-modified human hemoglobin improves microcirculatory blood flow and tissue oxygenation after hemorrhagic shock in awake hamsters. Crit Care Med (2003) 2.32
Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc Natl Acad Sci U S A (2003) 2.28
Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs. Adv Drug Deliv Rev (2004) 2.13
Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Deliv Rev (2004) 2.12
Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res (2002) 2.09
Balance between vasoconstriction and enhanced oxygen delivery. Transfusion (2008) 2.02
Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting. ACS Nano (2012) 1.86
Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. J Control Release (2004) 1.80
Lowering of blood pressure by increasing hematocrit with non nitric oxide scavenging red blood cells. Am J Respir Cell Mol Biol (2007) 1.70
Cell-penetrating peptides: breaking through to the other side. Trends Mol Med (2012) 1.68
Polyethylene glycol-diacyllipid micelles demonstrate increased acculumation in subcutaneous tumors in mice. Pharm Res (2002) 1.60
Microvascular perfusion upon exchange transfusion with stored red blood cells in normovolemic anemic conditions. Transfusion (2004) 1.59
Lipid modified triblock PAMAM-based nanocarriers for siRNA drug co-delivery. Biomaterials (2012) 1.59
Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating. Int J Pharm (2002) 1.58
Deep sternal wound infection after cardiac surgery: modality of treatment and outcome. Ann Thorac Surg (2005) 1.57
Microvascular pressure and functional capillary density in extreme hemodilution with low- and high-viscosity dextran and a low-viscosity Hb-based O2 carrier. Am J Physiol Heart Circ Physiol (2004) 1.53
Elevated plasma viscosity in extreme hemodilution increases perivascular nitric oxide concentration and microvascular perfusion. Am J Physiol Heart Circ Physiol (2004) 1.52
Microvascular and systemic effects following top load administration of saturated carbon monoxide-saline solution. Crit Care Med (2007) 1.51
Red cell age and loss of function: advance or SNO-job? Transfusion (2008) 1.51
Temporal and spatial variations of cell-free layer width in arterioles. Am J Physiol Heart Circ Physiol (2007) 1.46
Design, synthesis, and characterization of pH-sensitive PEG-PE conjugates for stimuli-sensitive pharmaceutical nanocarriers: the effect of substitutes at the hydrazone linkage on the ph stability of PEG-PE conjugates. Bioconjug Chem (2007) 1.43
One hundred fascia-sparing myocutaneous rectus abdominis flaps: An update. J Plast Reconstr Aesthet Surg (2010) 1.42
Vasoactive hemoglobin solution improves survival in hemodilution followed by hemorrhagic shock. Crit Care Med (2011) 1.41
Effects of fibrinogen concentrate after shock/resuscitation: a comparison between in vivo microvascular clot formation and thromboelastometry*. Crit Care Med (2013) 1.40
Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin Cancer Res (2009) 1.35
Paradoxical hypotension following increased hematocrit and blood viscosity. Am J Physiol Heart Circ Physiol (2005) 1.35
Dissociation of local nitric oxide concentration and vasoconstriction in the presence of cell-free hemoglobin oxygen carriers. Blood (2006) 1.32
Enhanced transfection of tumor cells in vivo using "Smart" pH-sensitive TAT-modified pegylated liposomes. J Drug Target (2007) 1.27
Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity. J Control Release (2011) 1.25
Self-assembling micelle-like nanoparticles based on phospholipid-polyethyleneimine conjugates for systemic gene delivery. J Control Release (2008) 1.22
Targeted O2 delivery by low-P50 hemoglobin: a new basis for O2 therapeutics. Am J Physiol Heart Circ Physiol (2003) 1.22
Enhanced binding and killing of target tumor cells by drug-loaded liposomes modified with tumor-specific phage fusion coat protein. Nanomedicine (Lond) (2010) 1.21
Effect of aggregation and shear rate on the dispersion of red blood cells flowing in venules. Am J Physiol Heart Circ Physiol (2002) 1.20
Organelle-targeted nanocarriers: specific delivery of liposomal ceramide to mitochondria enhances its cytotoxicity in vitro and in vivo. Nano Lett (2008) 1.19
Radiofrequency thermal ablation sharply increases intratumoral liposomal doxorubicin accumulation and tumor coagulation. Cancer Res (2003) 1.19
Microvascular oxygen distribution in awake hamster window chamber model during hyperoxia. Am J Physiol Heart Circ Physiol (2003) 1.19
Increased accumulation of PEG-PE micelles in the area of experimental myocardial infarction in rabbits. J Control Release (2004) 1.19
Liposomes targeted by fusion phage proteins. Nanomedicine (2008) 1.19
Hypoxia up-regulates expression of Eph receptors and ephrins in mouse skin. FASEB J (2005) 1.18
Polyethylene glycol-phosphatidylethanolamine conjugate (PEG-PE)-based mixed micelles: some properties, loading with paclitaxel, and modulation of P-glycoprotein-mediated efflux. Int J Pharm (2006) 1.17
Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies. Eur J Nucl Med Mol Imaging (2006) 1.17
Paclitaxel-loaded polymeric micelles modified with MCF-7 cell-specific phage protein: enhanced binding to target cancer cells and increased cytotoxicity. Mol Pharm (2010) 1.17
Combined radiofrequency ablation and adjuvant liposomal chemotherapy: effect of chemotherapeutic agent, nanoparticle size, and circulation time. J Vasc Interv Radiol (2005) 1.16
The cell-free layer in microvascular blood flow. Biorheology (2009) 1.15
A novel approach to blood plasma viscosity measurement using fluorescent molecular rotors. Am J Physiol Heart Circ Physiol (2002) 1.15
Nanopreparations to overcome multidrug resistance in cancer. Adv Drug Deliv Rev (2013) 1.14
Percutaneous tumor ablation: increased necrosis with combined radio-frequency ablation and intravenous liposomal doxorubicin in a rat breast tumor model. Radiology (2002) 1.14
Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines. Eur J Pharm Sci (2007) 1.14
P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells. Nanomedicine (Lond) (2012) 1.14
pO(2) measurements by phosphorescence quenching: characteristics and applications of an automated system. Microvasc Res (2003) 1.13
Design of multifunctional non-viral gene vectors to overcome physiological barriers: dilemmas and strategies. Int J Pharm (2011) 1.13
Nitric oxide regulation of microvascular oxygen exchange during hypoxia and hyperoxia. J Appl Physiol (1985) (2005) 1.13
Polymeric micelles for delivery of poorly soluble drugs: preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly(ethylene glycol)-lipid conjugate and positively charged lipids. J Drug Target (2005) 1.12
siRNA-containing liposomes modified with polyarginine effectively silence the targeted gene. J Control Release (2006) 1.12
Plasma viscosity regulates systemic and microvascular perfusion during acute extreme anemic conditions. Am J Physiol Heart Circ Physiol (2006) 1.12
Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes. Int J Pharm (2011) 1.12
Radio-frequency ablation increases intratumoral liposomal doxorubicin accumulation in a rat breast tumor model. Radiology (2002) 1.11
ATP-loaded liposomes effectively protect the myocardium in rabbits with an acute experimental myocardial infarction. Pharm Res (2005) 1.10
Role of endothelial nitric oxide in microvascular oxygen delivery and consumption. Free Radic Biol Med (2005) 1.09
"Smart" drug carriers: PEGylated TATp-modified pH-sensitive liposomes. J Liposome Res (2007) 1.09
Recent developments in lipid-based pharmaceutical nanocarriers. Front Biosci (Landmark Ed) (2011) 1.09
Polyethyleneimine-lipid conjugate-based pH-sensitive micellar carrier for gene delivery. Biomaterials (2012) 1.09
pH-sensitive poly(histidine)-PEG/DSPE-PEG co-polymer micelles for cytosolic drug delivery. Biomaterials (2012) 1.08
Do liposomal apoptotic enhancers increase tumor coagulation and end-point survival in percutaneous radiofrequency ablation of tumors in a rat tumor model? Radiology (2010) 1.07
Perfusion vs. oxygen delivery in transfusion with "fresh" and "old" red blood cells: the experimental evidence. Transfus Apher Sci (2010) 1.07
Liposomes loaded with paclitaxel and modified with novel triphenylphosphonium-PEG-PE conjugate possess low toxicity, target mitochondria and demonstrate enhanced antitumor effects in vitro and in vivo. J Control Release (2012) 1.06
A computer-based method for determination of the cell-free layer width in microcirculation. Microcirculation (2006) 1.06
Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting. J Drug Deliv (2013) 1.06
Arteriolar vasoconstrictive response: comparing the effects of arginine vasopressin and norepinephrine. Crit Care (2006) 1.06
PEG-PE micelles loaded with paclitaxel and surface-modified by a PBR-ligand: synergistic anticancer effect. Mol Pharm (2009) 1.05
Antinucleosome antibody-modified liposomes and lipid-core micelles for tumor-targeted delivery of therapeutic and diagnostic agents. J Liposome Res (2007) 1.05
Increase plasma viscosity sustains microcirculation after resuscitation from hemorrhagic shock and continuous bleeding. Shock (2005) 1.05
Synergy of photoacoustic and fluorescence flow cytometry of circulating cells with negative and positive contrasts. J Biophotonics (2012) 1.05
Current trends in liposome research. Methods Mol Biol (2010) 1.05
Poly(malic acid) nanoconjugates containing various antibodies and oligonucleotides for multitargeting drug delivery. Nanomedicine (Lond) (2008) 1.04
Extreme hemodilution with PEG-hemoglobin vs. PEG-albumin. Am J Physiol Heart Circ Physiol (2005) 1.04
Accumulation and toxicity of antibody-targeted doxorubicin-loaded PEG-PE micelles in ovarian cancer cell spheroid model. J Control Release (2012) 1.04